Change language

Sidebar content	Main content
Actions Displays	Guidance on the use of rituximab for recurrent or refractory Stage 3 or 4 follicular non-Hodgkin's lymphoma. Technology Appraisal Guidance - no. 37. 2002 Remove from selection Add to selection TitleGuidance on the use of rituximab for recurrent or refractory Stage 3 or 4 follicular non-Hodgkin's lymphoma. Technology Appraisal Guidance - no. 37. 2002 Author NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE PublisherNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE Year of publication2002 DimensionsA4 MaterialBook MaterialBook SubjectLYMPHOMA, DRUGS - PROPRIETARY MEDICINE

Main content

Guidance on the use of rituximab for recurrent or refractory Stage 3 or 4 follicular non-Hodgkin's lymphoma. Technology Appraisal Guidance - no. 37. 2002

Add to selection

TitleGuidance on the use of rituximab for recurrent or refractory Stage 3 or 4 follicular non-Hodgkin's lymphoma. Technology Appraisal Guidance - no. 37. 2002

Author

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

PublisherNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Year of publication2002

DimensionsA4

MaterialBook

SubjectLYMPHOMA, DRUGS - PROPRIETARY MEDICINE

AIS uses strictly necessary cookies to improve the user experience.

This AIS also uses analytical cookies.

Item request date
Expected return date
Destination